278 related articles for article (PubMed ID: 37376574)
1. A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose.
Beaudoin-Bussières G; Tauzin A; Dionne K; Gendron-Lepage G; Medjahed H; Perreault J; Levade I; Alfadhli L; Bo Y; Bazin R; Côté M; Finzi A
Viruses; 2023 May; 15(6):. PubMed ID: 37376574
[TBL] [Abstract][Full Text] [Related]
2. Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine.
Tauzin A; Nicolas A; Ding S; Benlarbi M; Medjahed H; Chatterjee D; Dionne K; Gong SY; Gendron-Lepage G; Bo Y; Perreault J; Goyette G; Gokool L; Arlotto P; Morrisseau C; Tremblay C; Martel-Laferrière V; De Serres G; Levade I; Kaufmann DE; Côté M; Bazin R; Finzi A
Cell Rep; 2023 Jan; 42(1):111998. PubMed ID: 36656710
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
4. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
[TBL] [Abstract][Full Text] [Related]
5. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
[TBL] [Abstract][Full Text] [Related]
7. Antibody-dependent NK-cell and neutralizing antibody responses against the Spike protein of Wuhan-Hu-1 and Omicron BA.1 SARS-CoV-2 variants in vaccinated experienced and vaccinated naïve individuals.
Albert E; Fernández-Soto D; Giménez E; Casanovas JM; Zulaica J; Álvarez-Rodríguez B; Rusu L; Geller R; Reyburn HT; Navarro D
J Med Virol; 2023 Jul; 95(7):e28900. PubMed ID: 37403730
[TBL] [Abstract][Full Text] [Related]
8. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1.
Balinsky CA; Jiang L; Jani V; Cheng Y; Zhang Z; Belinskaya T; Qiu Q; Long TK; Schilling MA; Jenkins SA; Corson KS; Martin NJ; Letizia AG; Hontz RD; Sun P
Front Immunol; 2023; 14():1266829. PubMed ID: 38077368
[TBL] [Abstract][Full Text] [Related]
10. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
[TBL] [Abstract][Full Text] [Related]
11. Cross neutralization of SARS-CoV-2 omicron subvariants after repeated doses of COVID-19 mRNA vaccines.
Luczkowiak J; Rivas G; Labiod N; Lasala F; Rolo M; Lora-Tamayo J; Mancheno-Losa M; Rial-Crestelo D; Pérez-Rivilla A; Folgueira MD; Delgado R
J Med Virol; 2023 Jan; 95(1):e28268. PubMed ID: 36319593
[TBL] [Abstract][Full Text] [Related]
12. Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy.
Bartsch YC; Atyeo C; Kang J; Cai Y; Chen B; Gray KJ; Edlow AG; Alter G
Am J Obstet Gynecol; 2022 Sep; 227(3):493.e1-493.e7. PubMed ID: 35430229
[TBL] [Abstract][Full Text] [Related]
13. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
Duty JA; Kraus T; Zhou H; Zhang Y; Shaabani N; Yildiz S; Du N; Singh A; Miorin L; Li D; Stegman K; Ophir S; Cao X; Atanasoff K; Lim R; Mena I; Bouvier NM; Kowdle S; Carreño JM; Rivero-Nava L; Raskin A; Moreno E; Johnson S; Rathnasinghe R; Pai CI; Kehrer T; Cabral EP; Jangra S; Healy L; Singh G; Warang P; Simon V; Sordillo EM; van Bakel H; Liu Y; Sun W; Kerwin L; Teijaro J; Schotsaert M; Krammer F; Bresson D; García-Sastre A; Fu Y; Lee B; Powers C; Moran T; Ji H; Tortorella D; Allen R
Med; 2022 Oct; 3(10):705-721.e11. PubMed ID: 36044897
[TBL] [Abstract][Full Text] [Related]
14. Clinical virology and effect of Covid-19 vaccination and monoclonal antibodies against highly infectious SARS- CoV-2 omicron sub variant BF.7 (BA.5.2.1.7): A systematic review.
Chenchula S; Amerneni KC; Ghanta MK; Padmavathi R; Chandra MB; Adusumilli MB; Chavan M; Mudda S; Gupta R; Lakhawat B
Virology; 2023 Jul; 584():38-43. PubMed ID: 37229914
[TBL] [Abstract][Full Text] [Related]
15. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine.
Debes AK; Xiao S; Egbert ER; Caturegli P; Gadala A; Colantuoni E; Sitaras I; Pekosz A; Milstone AM
Microbiol Spectr; 2022 Oct; 10(5):e0204622. PubMed ID: 36190405
[TBL] [Abstract][Full Text] [Related]
17. Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS-CoV-1 survivors after two doses of CoronaVac plus one dose subunit vaccine.
Chen D; Li X; Hao X; Qiu Y; Song Y; Sun H; Liu Y; Du J; Zhang Y; Xiao F; Song C; Yan Y; Song R; Wang X; Zhao X; Jin R
J Med Virol; 2023 Oct; 95(10):e29136. PubMed ID: 37804496
[TBL] [Abstract][Full Text] [Related]
18. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
[TBL] [Abstract][Full Text] [Related]
20. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
